Equillium, Inc. Employee Directory
Biotechnology ResearchCalifornia, United States11-50 Employees
Equillium, Inc. is a clinical-stage biotechnology company based in San Diego, California, focused on immunobiology to address severe autoimmune and inflammatory diseases with high unmet medical needs. Its approach seeks to restore balance to the immune system to improve patient outcomes. The lead candidate, itolizumab, is a first-in-class monoclonal antibody targeting the CD6-ALCAM signaling pathway, with development focused on immuno-inflammatory disorders such as acute graft-versus-host disease, lupus nephritis, and uncontrolled asthma. Equillium operates as a small, specialized team within the biotechnology research sector. In April 2026, the company announced participation in Oppenheimer's Innovation on the Island Event, indicating ongoing engagement with investors and the broader scientific community.